Seattle Children’s Research Institute today announced the Invent at Seattle Children’s Postdoctoral Scholars Program, a $45 million investment in training early career scientists historically underrepresented in biotech in the development of therapeutics for childhood conditions. Seattle Children’s has pledged to raise an additional $10 million for the program. “We want to create an on-ramp to […]
As a high school freshman, Liesel Von Imhof had a dream of attending college at Harvard. She packed her schedule with challenging classes and participated in varsity sports such as cross-country running and cross-country skiing. She had occasional, debilitating headaches that sometimes caused her to miss school, but she blamed them on stress, dehydration or […]
The U.S. Food and Drug Administration on Feb. 5 approved Bristol Myers Squibb’s Breyanzi, a chimeric antigen receptor (CAR) T-cell therapy used to treat adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after standard treatments. The approval was supported by research at Seattle Children’s, including the […]